Replimune (REPL) Asset Writedowns and Impairment (2026)
Replimune (REPL) posted Asset Writedowns and Impairment of $273000.0 for Q4 2023, up 6.64% sequentially from $256000.0 in Q3 2023, and up 16.17% YoY from $235000.0 in Q4 2022.
Powered by 
Analysis
Replimune (REPL) Asset Writedowns and Impairment (2026) Analysis & Trends
Replimune has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $273000.0 in Q4 2023.
- Quarterly Asset Writedowns and Impairment rose 16.17% year-over-year to $273000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (changed N/A YoY) and the FY2026 annual result came in at $188000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $273000.0 in Q4 2023 per REPL's latest filing, from $256000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $273000.0 in Q4 2023 and troughed at $235000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - |